News Summary

Sherbrooke, Quebec-based medtech startup Tatum Bioscience has showcased promising results with its innovative immunotherapy designed to combat cancer. In a recent study published in the Journal for Immunotherapy of Cancer, Tatum’s approach demonstrated the ability to ‘uncloak’ cancer cells in mice, allowing the immune system to target and eliminate tumors effectively. This breakthrough is significant as it suggests potential long-term immune protection against specific cancers, functioning similarly to a vaccine. Tatum’s unique method utilizes bioengineered nanofilaments that bind to cancer cells, marking them for immune attack, which could offer a scalable alternative to conventional personalized cancer vaccines. The startup, founded in 2019, is now seeking additional funding to move towards clinical trials, having raised $5.8 million so far from investors including BoxOne Ventures and ACET Capital. Tatum’s approach is gaining attention amid a challenging funding environment for Canadian life sciences startups.